Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective. - Test2 - elhamkhani - TriplyDB

Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.

Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.

http://www.wikidata.org/entity/Q35119475

about

A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders Costs of a motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice for pregnant substance users The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility.Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial.The cost-effectiveness of therapies to treat alcohol use disorders.Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions.

P2860

Q27000732-CA4CB67D-8AEE-407E-A4C3-439FE02AA351 Q28538168-948AB1CE-A459-4274-B46B-13E946DB5E94 Q35087485-382097EE-1811-4E3A-80BF-99CADDBAF91F Q35752035-9CFD0F4D-0D8C-4EC6-811F-950AA9688869 Q37143517-A1D74B08-A235-4DBA-8263-42F754F6CCF6 Q47599832-B9E7F544-43B7-436F-A164-0C7E3DA2E180 Q49605183-237D9FCD-22AD-461B-9D62-B7003557CED1

P2860

Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.

http://www.wikidata.org/entity/Q35119475

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Revisiting the cost-effectiven ...... ents: the patient perspective.

@ast

Revisiting the cost-effectiven ...... ents: the patient perspective.

@en

type

label

Revisiting the cost-effectiven ...... ents: the patient perspective.

@ast

Revisiting the cost-effectiven ...... ents: the patient perspective.

@en

prefLabel

Revisiting the cost-effectiven ...... ents: the patient perspective.

@ast

Revisiting the cost-effectiven ...... ents: the patient perspective.

@en

P1433

Q35119475-0DF3DC79-69A8-4FE7-BF72-3E84F63135A7

P1476

Q35119475-71F0BDC3-926F-4E42-B21E-BAE271382EAB

P2093

Q35119475-1642A612-2DB4-4A4D-A32E-B279A1FC2096

Q35119475-28962B10-A027-4A35-83A8-3C4F6DD1B41D

Q35119475-49A6DAEC-FA96-41F1-BC43-2C248ECD0536

Q35119475-72743AF0-D44E-4199-8848-A091118BC612

Q35119475-90BB7935-A356-4F40-A055-695C82549571

Q35119475-9B60AABA-E5DD-4957-A5D5-859B22566B8B

Q35119475-B7816ECB-1442-47A0-AC12-434319FCCD37

Q35119475-FF411D6A-30FC-40CD-A365-B6D8516CA12C

P2860

Q35119475-160DE330-9458-4467-AD0F-7B45F890E32A

Q35119475-35D562BC-D156-4DA0-9F57-978DB308113F

Q35119475-665B6233-A0D7-4116-A16F-14768425A5A9

Q35119475-678D8FB2-DEB6-41B9-8510-490FA93524F9

Q35119475-69AD3486-E4CC-4428-B8D7-20C4D0E7C15B

Q35119475-722FD3F0-4C48-4129-8539-CDBFAC0E571E

Q35119475-732C8616-6692-482A-B41F-585DB4C7EEB0

Q35119475-857AFA66-CB1F-4FBB-B421-289C3B860E50

Q35119475-8F2834D1-51FF-4E72-8A7D-452119ECCC85

Q35119475-9E959D12-63FD-41F1-978B-F503CC34ED71

P304

Q35119475-9911DF34-8D85-476E-9844-D1243E934B14

P31

Q35119475-26DF690F-99AA-44E5-A355-9302459BF4C4

P356

Q35119475-F1816C2E-C0C0-4AA9-BD6E-61E2E581CF47

P433

Q35119475-61F4F84D-B59F-4AD7-8EF5-F05D791DBBC4

P478

Q35119475-3CE42E1E-B512-4D51-928D-385A7970FD46

P577

Q35119475-E3313B4D-6A5B-41B9-BEE3-FA5AEEABB382

P698

Q35119475-9D7B29A5-C826-45A2-A202-FF554CBF9C29

P921

Q35119475-A417D9EA-CFDD-4824-99B9-FA5ED9FEB752

P932

Q35119475-FC78E290-38A7-4D1A-8279-9B046129BCF5

P356

MLR.0B013E3181CA3D40

P1433

P1476

Revisiting the cost-effectiven ...... ents: the patient perspective.

@en

P2093

Daniel R Kivlahan

http://www.w3.org/2001/XMLSchema#string

Gary A Zarkin

http://www.w3.org/2001/XMLSchema#string

J Scott Tonigan

http://www.w3.org/2001/XMLSchema#string

James R McKay

http://www.w3.org/2001/XMLSchema#string

Jeremy W Bray

http://www.w3.org/2001/XMLSchema#string

Laura J Dunlap

http://www.w3.org/2001/XMLSchema#string

Michael Mills

http://www.w3.org/2001/XMLSchema#string

Patricia Latham

http://www.w3.org/2001/XMLSchema#string

P2860

Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.

Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.

Cost methodology of COMBINE.

Measurement of drinking behavior using the Form 90 family of instruments.

Who goes to alcohol and drug treatment? Understanding utilization within the context of insurance.

Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.

Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP).

P304

306-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MLR.0B013E3181CA3D40

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20355261

http://www.w3.org/2001/XMLSchema#string

P921

P932

3140763

http://www.w3.org/2001/XMLSchema#string